About This Course

HIV-associated tuberculosis remains the major cause of death among HIV-infected individuals. New knowledge on how we can improve our efforts of effective prevention, early diagnosis and treatment of drug-susceptible TB and drug-resistant TB in HIV-infected individuals has been acquired. The most important latest developments and new recommendations being relevant for your daily practice will be discussed.

This 2 weeks course was prepared in collaboration with 3 reviewers from AHF: Dr. Adele Schwartz Benzaken, Senior Global Medical Director, Dr. Fernanda Moreira Rick, Associate Global Medical Director, and Dr. Jan van den Hombergh, Director Global Quality, and will be awarded with 3.0 AHF CME credit hours.